MedTrace Logo

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

NCT01488318 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-01-05

Study results available
· View outcomes & findings →

Summary

This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema).

The primary endpoint 12-week PFS.

Conditions

  • Squamous Cell Carcinoma Of The Head And Neck

Interventions

DRUG

Cetuximab

Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1

DRUG

Dasatinib

Dasatinib 150 mg po

Sponsors & Collaborators

Principal Investigators

  • Julie Bauman · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2016-01-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488318 on ClinicalTrials.gov